CommercialCoverageLow impact
08.00.69d, Agalsidase beta (Fabrazyme®) and pegunigalsidase alfa-iwxj (Elfabrio)
Independence Blue Cross·Endocrinology, Nephrology, Cardiology·Pharmacy
Effective date
May 28, 2025
We identified it
Jun 19, 2026
Summary
A commercial policy for Agalsidase beta (Fabrazyme®) and pegunigalsidase alfa-iwxj (Elfabrio) has been reissued and will take effect on 05/28/2025. This policy update affects specialty pharmacy billing for these rare disease medications used to treat Fabry disease.
Action Required
By May 28, 2025: Billing team should review the full policy details at the provided URL to understand any changes to coverage, prior authorization, or billing requirements for Fabrazyme and Elfabrio. Update any relevant billing protocols or prior authorization workflows for these specialty medications.